InMed Pharmaceuticals Inc.
INM
1.42 $
1 day: 0.0% (0.00 $)
The alert is saved directly without jumping back to the homepage.
Price alerts for INM
Please log in to view and save price alerts.
Finanzen
Company info
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Aktuelle News
-
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Vorschau anzeigen
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.As previously disclosed, the Company was notified by Nasdaq
-
INM Stock Alert: What to Know as InMed, Mentari Announce Merger
Vorschau anzeigen
InMed stock rallied yesterday on a merger announcement with Mentari Therapeutics. Here’s why the transaction is concerning for INM investors.
-
/C O R R E C T I O N -- InMed Pharmaceuticals/
Vorschau anzeigen
InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is pleased to announce that it has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp. a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC, a wholly-owned subsidiary of InMed. The merger brings together Mentari's differentiat
-
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
Vorschau anzeigen
The merger shifts InMed toward migraine prevention therapies while a large private financing is expected to fund operations through key clinical milestones. Key Investor TakeawaysInMed Pharmaceuticals (NASDAQ:INM) announced an all-stock merger with private biotech company Mentari Therapeutics focused on migraine prevention therapies.
-
A migraine drugmaker heads to the public markets through reverse merger
Vorschau anzeigen
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.